Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...

95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% ...

(RTTNews) - Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzi's approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from his presentation on extranodal marginal zone ...

Long-term data showed that the addition of Imbruvica did not improve overall survival in patients with marginal zone lymphoma or mantle cell lymphoma. The pharmaceutical companies developing Imbruvica ...

Please provide your email address to receive an email when new articles are posted on . The results were presented at Society of Hematologic Oncology’s Annual Meeting. “We currently are really missing ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda This retrospective cohort study included patients ...

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. This is an ASCO Meeting Abstract from the 2012 ASCO ...

HOUSTON -- Already indicated for relapsed/refractory follicular lymphoma, the bispecific antibody mosunetuzumab (Lunsumio) showed early promise for improving outcomes in two key lymphoma subtypes, ...

Credit: Bristol Myers Squibb. The approval was based on data from the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. Breyanzi is prepared from the patient’s T cells, which are ...